Quantifying the persisting orphan-drug shortage public health crisis in the United States

Figures & data

Table 1. Number of OD approvals by therapeutic area.

	Rheumatology	Nephrology	Antidotes	Gastroenterology	Respiratory	Immunology	Others	Cardiovascular	Ophthalmology	Anti-infectives	Neurology	Hematology	Endocrinology	Oncology
Number of OD approvals	12	13	14	15	16	24	30	31	33	48	48	54	63	150
Percentage of all ODs	2%	2%	2%	3%	3%	4%	5%	5%	6%	8%	8%	9%	11%	26%

Figure 1. Number of new OD approvals per year.

Figure 2. Cumulative number of FDA-approved ODs on the US market by year.

Figure 3. Yearly distribution of new OD shortages.

Figure 4. Number of active OD shortages in a given year (with a minimal shortage duration of one day).

Figure 5. Percentage of ODs on the market that were in shortage in a given year for at least one day.

Figure 6. Duration of individual shortages starting in a given year. Note: Red bars indicateshortages unresolved at the date of data collection (13 June 2016).

Table 2. Distribution of shortages among therapeutic areas.

	Antidotes	Anti-infectives	Cardiovascular	Endocrinology	Gastroenterology	Hematology	Immunology	Nephrology	Neurology	Oncology	Ophthalmology	Others	Respiratory	Rheumatology	Total
Number of shortages	0	3	4	14	3	4	0	2	5	19	3	4	1	4	66
Number of ODs	14	48	31	63	15	54	24	13	48	150	33	30	16	12	569
Percentage of ODs affected by shortage	0%	6%	13%	22%	20%	7%	0%	15%	10%	13%	9%	13%	6%	33%	12%